Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The controversial head of the AIDS Healthcare Foundation has taken his PrEP-skepticism campaign to the prestigious medical journal AIDS.
The science behind Truvada as pre-exposure prophylaxis reveals an awesome tool that is apparently already helping shrink U.S. HIV rates.
The letter “O” was misread as the number “0.” Here’s what that “O” stood for.
A new study examines factors that predicted which black men who have sex with men (MSM) would better stick with the daily Truvada regimen.
The trial will test giving the treatment every four weeks, which has controlled HIV better than the eight-week dosing schedule.
Research suggests that some people are taking hep C therapy for longer periods than they actually need.
Watch videos of Shandi, Prada and more to mark the April 18 debut of NTHTD.
A single infusion of zoledronic acid is linked with protection against bone loss for up to a year among those starting HIV treatment.
Gilead’s investigational hepatitis C treatment Sovaldi/velpatasvir can be combined safely with most boosted HIV treatments.
A household-based program offering HIV testing, linkage to medical care and immediate treatment for the virus has shown promise.
NIAID research will build on the ASPIRE trials. Those findings showed that dapivirine rings provided “modest” HIV protection.
Awareness and use of Truvada as PrEP among men who have sex with men has risen significantly, particularly in a few major cities.
Curing hepatitis C virus (HCV) is associated with a reduced risk of death, kidney disease and diabetes.
A review of important hep C-related medical research presented at a recent medical conference focusing on retroviruses.
HIV-positive gay and bi men are more likely to be acutely (very recently) infected with hepatitis C if they have casual sex partners.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.